Dr. Donders' Vulvodynia Study Published in Journal of Lower Genital Tract Disease
~Study suggests Cutaneous Lysate helps reduce pain during intercourse~
NEW YORK, Nov. 6, 2012 /PRNewswire/ -- The results from Dr. Gilbert G. Donders ' (MD, PhD) study testing Cutaneous Lysate in women suffering from vulvar pain were reported in the Journal of Lower Genital Tract Disease in the October 2012 issue (Volume 16).
The placebo-controlled study aimed to evaluate the safety and efficacy of Cutaneous Lysate in the treatment of provoked vestibulodynia; a form of a vulvar pain symptom called vulvodynia. Provoked vestibulodynia (formally known as vulvar vestibulitis) is characterized as a local, sharp pain occurring in response to touch or pressure to the vulva.
The study included 30 females with provoked vestibulodynia. The subjects applied either a cream with Cutaneous Lysate or its placebo twice daily to the vulva over a three-month period with a one-week wash-out phase, followed by another three months period with the cross-over product.
The study indicated that the Cutaneous Lysate was effective in helping to reduce pain during intercourse in females suffering from provoked vestibulodynia. In the first 12 weeks of use, those using Cutaneous Lysate showed a significant reduction of pain during sexual activity whereas those using the placebo did not. The study also provided some evidence that the females who acquired vestibulodynia seem more responsive to the treatment.
Although a cure for provoked vulvodynia has not been found as of yet, Cutaneous Lysate is a promising new treatment for women suffering from vulvar pain.
Neogyn® Vulvar Soothing Cream is a cosmetic product to help soothe and comfort the vulva. Formulated with Cutaneous Lysate, a naturally balanced blend of proteins discovered in Switzerland, the cream is non-greasy, fast absorbing and free of color additives, fragrances and analgesics. Recommended by physicians and women's health professionals, Neogyn® has a unique, patented blend of naturally balanced proteins that help restore well-being and comfort with twice daily use over a period of at least 6 to 8 weeks.
More by this Source
Sexual Dysfunction Linked To Antidepressant Use In Female Patients
Feb 19, 2013, 11:57 ET
Sexual Dysfunction Common In Type II Diabetes Patients
Jan 22, 2013, 10:31 ET
NeoGyn® Launches New Advertising Campaign
Dec 04, 2012, 13:19 ET
Browse our custom packages or build your own to meet your unique communications needs.
Learn about PR Newswire services
Request more information about PR Newswire products and services or call us at (888) 776-0942.